Soleno Therapeutics (SLNO) reported preliminary Q4 net revenue Monday of $90 million to $92 million.

Analysts surveyed by FactSet expect $83.3 million.

The biotech company also said it has achieved profitability and positive cash flow and reported preliminary cash, cash equivalents and marketable securities of $500 million as of Dec. 31.

Shares of the company were up more than 3% in recent Monday premarket activity.